TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. (TGTX) on November 9, 2020. The report discloses the launch of an "at the market" (ATM) offering of the Company's common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The document focuses exclusively on the authorization of a new equity issuance mechanism.
Material Changes and Events
On November 9, 2020, the Company initiated an ATM offering pursuant to an existing At Market Issuance Sales Agreement dated March 20, 2020. The agreement involves the following agents:
- Jefferies LLC
- Cantor Fitzgerald & Co.
- B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.)
Under the agreement, the Company may sell shares of its common stock ($0.001 par value) through the agents using methods deemed "at the market offerings" under Rule 415 of the Securities Act of 1933. The Company is not obligated to sell any shares.
Guidance, Outlook, and Terms
The filing outlines the terms of the sales agreement rather than providing operational guidance. Key terms include:
- Commission: The Company will pay the agents a commission of up to 3.0% of the gross proceeds from any shares sold.
- Sales Parameters: The Company determines the number of shares, dates, and minimum price for sales.
- Legal Counsel: Alston & Bird LLP provided an opinion on the offering, filed as Exhibit 5.1.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the immediate need for capital raised via this ATM facility.
- Review the original Sales Agreement (Exhibit 1.1 from March 20, 2020) for any specific limitations on the total number of shares available for sale.
- Monitor subsequent filings for actual sales volumes and pricing to gauge market reception and dilution impact.
- Confirm the Company's pipeline status and clinical trial milestones to evaluate the strategic use of proceeds.